Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 4Active not recruiting 1

Sponsor Class

OTHER 11INDUSTRY 5

Study Type

Observational 4Interventional 1

Sponsor

Cancer Type

Classical hematology 5

Conditions

Venous Thromboembolism 5Neoplasms 4Treatment of Venous Thromboembolism in Cancer Patients 3Venous Thrombosis 1Pulmonary Embolism 1Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery 1Embolism 1

Interventions

apixaban 5Rivaroxaban 5Dalteparin 4Enoxaparin 3edoxaban 2abelacimab 2Tinzaparin 2MAA868 2Heparin, Low-Molecular-Weight 2Dabigatran 2isoquercitrin 1calcium heparin 1betrixaban 1bemiparin 1Warfarin 1Heparin 1Gemcitabine 1Fondaparinux 1AVE 5026 1ALT-836 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Venous Thromboembolism × Rivaroxaban × Clear all
NCT04618913 2026-05-26

VICTORIE

Pfizer

Active not recruiting
1 enrolled
Classical hematology

Embolism, Neoplasms, Venous Thromboembolism

NCT05461807 2022-10-26

H2H-OSCAR-US

Bayer

Completed
2,437 enrolled
Classical hematology

Neoplasms, Venous Thromboembolism

NCT03965741 2021-11-30

PRACTISE

Bayer

Completed
97,765 enrolled
Classical hematology

Venous Thromboembolism

NCT02555878 2019-09-12

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

Janssen Research & Development, LLC

Phase 3 Completed
841 enrolled 24 charts
Classical hematology

Neoplasms, Venous Thromboembolism

NCT03214172 2018-09-06

Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

Bayer

Completed
1,000 enrolled
Classical hematology

Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡